MINNEAPOLIS, Minnesota — The U.S. Food and Drug Administration approved a Medtronic deep brain stimulation treatment to treat obsessive compulsive disorder – the first deep brain stimulation treatment ...
Medical tech company Medtronic has just landed FDA clearance on its Deep Brain Stimulation (DBS) Clinical Programmer and ActivaProgramming application. "This marks a new era of innovation from the ...
DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first ...
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever There is no cure for debilitating ...
On Monday, the FDA approved Medtronic plc’s (NYSE:MDT) BrainSense Adaptive deep brain stimulation (aDBS) and BrainSense Electrode Identifier (EI) for patients with Parkinson’s disease. Deep brain ...
Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...
MINNEAPOLIS--(BUSINESS WIRE)-- In the largest, randomized, controlled study of deep brain stimulation (DBS) for Parkinson’s disease, Medtronic DBS Therapy was shown to improve motor function for up to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Medtronic said Monday the U.S ...
Medtronic plc secured CE mark approval under the EU Medical Device Regulation for its Brainsense adaptive deep brain stimulation system. The technology represents a major advancement in the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results